nenocorilant / Corcept Therap - LARVOL DELTA

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Corcept Therapeutics

New P1/2 trial • Oncology • Solid Tumor

Nenocorilant in Combination with Immunotherapy (Businesswire) - "Solid tumors - Phase 1b dose-finding trial of nenocorilant, our proprietary selective glucocorticoid receptor antagonist, plus nivolumab in 30 patients with a variety of solid tumors to begin in coming weeks - nenocorilant’s first study in patients."

New P1 trial • Solid Tumor